MedservRegis (MAL:MDS) Research & Development: €0.0 Mil (TTM As of Dec. 2025)


MAL:MDS MedservRegis PLC MAL:MDS
45 GF Score
Price €0.69
GF Value €0.91
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is MedservRegis Research & Development?

MedservRegis MAL:MDS 45 Research & Development is €0.0 Mil as of Dec. 2025. GuruFocus rates MAL:MDS with a GF Score™ of 45/100 and a GF Value™ of €0.91 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. MedservRegis's Research & Development for the six months ended in Dec. 2025 was €0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €0.0 Mil.

MedservRegis  (MAL:MDS) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

MedservRegis Research & Development Related Terms

MedservRegis Research & Development Historical Data

* Premium members only.

The historical data trend for MedservRegis's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MedservRegis Research & Development Chart

MedservRegis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MedservRegis Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MAL:MDS
45GF Score
MedservRegis PLC MAL:MDS
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MedservRegis Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.0 Mil mean?
MedservRegis (MAL:MDS) has a Research & Development of €0.0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on MedservRegis and its competitors.
Is MedservRegis' Research & Development too high?
MedservRegis' current Research & Development is €0.0 Mil. Overall, MedservRegis has a GF Score™ of 45/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MedservRegis' Research & Development compare to SLB and BKR?
MedservRegis' Research & Development of €0.0 Mil can be compared against companies in the Oil & Gas industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for an Oil & Gas company?
A good Research & Development depends on the Oil & Gas industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on MedservRegis and its competitors. MedservRegis's current Research & Development is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedservRegis stock overvalued right now?
Based on GuruFocus' analysis, MedservRegis (MAL:MDS) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.91, compared to a current price of €0.69 — trading 24.2% below its estimated fair value. The current Research & Development is €0.0 Mil. MedservRegis' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For MedservRegis (MAL:MDS), the current Research & Development is €0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MedservRegis (MAL:MDS) Overvalued in 2026?

Based on GuruFocus' analysis, MedservRegis stock appears to be undervalued. The current stock price of €0.69 is trading 24.2% below its estimated GF Value™ of €0.91. GuruFocus considers MedservRegis to be Modestly Undervalued.

Key valuation signals for MAL:MDS:

  • Research & Development: €0.0 Mil
  • GF Value™: €0.91 vs. price of €0.69 (24.2% below fair value)
  • GF Score™: 45/100 with 5 warning signs

No single metric tells the full story. See the MAL:MDS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MedservRegis Business Description

Industry EnergyOil & Gas
Address Malta Freeport, Port of Marsaxlokk, Birzebbugia, MLT, BBG 3011
MedservRegis PLC is engaged in providing shore-based logistics to the offshore oil and gas industry and engineering and supply chain management for oil country tubular goods (OCTG) to support the onshore oil and gas industry. Its segment includes Integrated logistics support services; Oil country tubular goods; Trading activity and Photovoltaic farms. The company generates maximum revenue from the Integrated logistics support services segment, that Includes the provision of comprehensive logistical support services to the offshore oil and gas industry from the group's bases in Malta, Cyprus, Egypt, South America, and Africa.
45GF Score

Get the complete analysis for MAL:MDS

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.69
Price
€0.91
GF Value